Endo Health Solutions (NASDAQ:ENDP) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued to investors on Wednesday, Analyst RN reports. They currently have a $70.00 target price on the stock. Zacks‘ price target would suggest a potential upside of 4.52% from the stock’s previous close.
Zacks‘ analyst wrote, “Endo Health reported higher-than-expected earnings in the third quarter of 2013 aided by lower costs. The company raised its earnings guidance for 2013 in the range of $4.60-$4.75. We are impressed by Endo’s growth by acquisition strategy. The impending acquisition of generics company Boca Pharmacal is a smart move by Endo to strengthen its Qualitest portfolio and combat the generic threat over its key products. We are also positive on Endo’s decision to buy Paladin Labs. Moreover, we are encouraged by Endo’s move to sell its struggling anatomical pathology business. We believe that the current price reflects all the positives and hence revert to a Neutral recommendation on the stock.”
A number of other analysts have also recently weighed in on ENDP. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Endo Health Solutions in a research note to investors on Tuesday, November 12th. They now have a $70.00 price target on the stock, up previously from $43.00. Separately, analysts at UBS AG raised their price target on shares of Endo Health Solutions from $50.00 to $63.00 in a research note to investors on Wednesday, November 6th. They now have a “buy” rating on the stock. Finally, analysts at Susquehanna raised their price target on shares of Endo Health Solutions from $42.00 to $62.00 in a research note to investors on Wednesday, November 6th. They now have a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $50.56.
Shares of Endo Health Solutions (NASDAQ:ENDP) traded up 0.18% during mid-day trading on Wednesday, hitting $67.09. 358,054 shares of the company’s stock traded hands. Endo Health Solutions has a 52-week low of $25.01 and a 52-week high of $67.23. The stock’s 50-day moving average is $52.8 and its 200-day moving average is $42.74. The company’s market cap is $7.708 billion.
Endo Health Solutions (NASDAQ:ENDP) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.34 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.11 by $0.23. The company had revenue of $715.00 million for the quarter, compared to the consensus estimate of $695.63 million. During the same quarter last year, the company posted $1.28 earnings per share. Endo Health Solutions’s revenue was down 4.7% compared to the same quarter last year. Analysts expect that Endo Health Solutions will post $4.72 EPS for the current fiscal year.
Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.